Clinical bottom line
Anti-CD38 monoclonal antibodies, increasingly used in autoimmune diseases, pose a distinct infectious risk profile that warrants careful clinical management. These therapies can impair immune surveillance by targeting CD38-expressing immune cells, potentially increasing susceptibility to bacterial, viral, and mycobacterial infections. Current evidence suggests heightened vigilance for serious infections, including opportunistic pathogens, is necessary during treatment. Prophylactic strategies and close monitoring should be individualized, especially in patients with additional immunosuppressive risk factors. However, data remain limited, and clinical decisions should balance infection risk against therapeutic benefit (Moreau et al., 2015).
What the evidence shows
Anti-CD38 monoclonal antibodies, such as daratumumab and emerging agents like MOR03087 and TAK-079, target CD38, a glycoprotein broadly expressed on plasma cells and subsets of immune cells. This targeting can lead to depletion or functional impairment of these cells, which are integral to humoral immunity and immune regulation (Moreau et al., 2015; Definitions, 2020).
Moreau et al. (2015) provide a practical overview highlighting that patients receiving anti-CD38 antibodies may experience increased risk of infections, including bacterial pneumonia, herpes zoster reactivation, and mycobacterial infections. These risks are compounded in autoimmune disease populations often receiving concomitant immunosuppressants. The Emerging Infections Network study by Winthrop et al. (2008), although focused on anti-TNF and other biologics, underscores the importance of recognizing serious infections in patients on novel immunomodulatory therapies, a principle applicable to anti-CD38 agents.
Emerging anti-CD38 antibodies such as MOR03087 and TAK-079 are under investigation for autoimmune indications, with preliminary safety data indicating similar infection risks as established anti-CD38 therapies (Definitions, 2020). Bispecific antibodies targeting CD38 (e.g., GBR 1342, AMG 424) may further modulate immune responses, but clinical infection data remain sparse (Definitions, 2020).
Caveats and uncertainty
The bulk of clinical experience with anti-CD38 antibodies derives from hematologic malignancy treatment, particularly multiple myeloma, where infection risk is influenced by disease-related immunosuppression and prior therapies. Extrapolation to autoimmune disease populations must be cautious, as baseline immune status and concomitant treatments differ.
Published data specifically addressing infection incidence and management in autoimmune disease patients receiving anti-CD38 monoclonal antibodies are limited. The heterogeneity of autoimmune diseases and treatment regimens complicates risk stratification. Furthermore, long-term infection risk and optimal prophylactic strategies remain undefined.
The Emerging Infections Network data (Winthrop et al., 2008) highlight the potential for serious infections with novel biologics but predate widespread anti-CD38 use in autoimmunity. Thus, ongoing pharmacovigilance and prospective studies are needed to clarify infection risks and guide management.
How this may change practice
Clinicians managing autoimmune disease patients on anti-CD38 monoclonal antibodies should incorporate infection risk assessment into treatment planning. This includes baseline screening for latent infections (e.g., tuberculosis, herpesviruses), consideration of vaccination status, and patient education on infection signs.
During therapy, heightened surveillance for infections is warranted, with a low threshold for diagnostic evaluation and early antimicrobial intervention. Prophylactic antiviral or antibacterial agents may be considered in high-risk patients, although evidence-based guidelines specific to anti-CD38 therapies in autoimmunity are lacking.
Multidisciplinary collaboration between infectious disease specialists and treating clinicians can optimize individualized infection prevention and management strategies. As emerging anti-CD38 agents and bispecific antibodies enter clinical use, clinicians should remain alert to evolving safety data and emerging consensus recommendations.